Jillian Hall

Dr. Jillian Hall


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2023 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
Estefania OliverosEstefania Oliveros
Estefania Oliveros
CGClara Inés Saldarriaga Giraldo
Clara Inés Saldarriaga Giraldo
JHJillian Hall
Jillian Hall
ETElizabeth Tinuoye
Elizabeth Tinuoye
MRMaria Juliana Rodriguez
Maria Juliana Rodriguez
JCJohanna Contreras
Johanna Contreras

4 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JCJohanna Contreras
Johanna Contreras
JNJeremy Nussbaum
Jeremy Nussbaum
PCPeter Cangialosi
Peter Cangialosi
STSahityasri Thapi
Sahityasri Thapi
ARAnkitha Radakrishnan
Ankitha Radakrishnan
ASAlejandro Folch Sandoval
Alejandro Folch Sandoval
Minoritized racial and ethnic groups suffer disproportionately from the incidence and morbidity of pulmonary hypertension (PH), as well as its associated cardiovascular, pulmonary, and systemic conditions. These disparities are largely explained by social determinants of health, including access to care, systemic biases, socioeconomic status, and environment. Despite this undue burden, minority patients remain underrepresented in PH research. Steps should be taken to mitigate these disparities, including initiatives to increase research participation, combat inequities in access to care, and improve the treatment of the conditions associated with PH.

8 August 2024 in Journal of Electrocardiology
Verified
Journal Article
Closed access
JHJillian Hall
Jillian Hall
DEDaniel Edmundowicz
Daniel Edmundowicz
ECEdmond Cronin
Edmond Cronin

Verified
Journal Article
Open access
PDF file
SHSteven Hopkins
Steven Hopkins
JHJillian Hall
Jillian Hall
HSHollie Saunders
Hollie Saunders
RBRiyaz Bashir
Riyaz Bashir
VLVladimir Lakhter
Vladimir Lakhter
Estefania OliverosEstefania Oliveros
Estefania Oliveros
Background: Sarcopenia, or loss of skeletal muscle mass, has been associated with poor outcomes (e.g., functional decline, increased mortality, and low quality of life), but its role in CTEPH remains unclear. The psoas muscle index (PMI) is a validated measure of sarcopenia. We investigated the incidence of sarcopenia using PMI in CTEPH. Methods: Retrospective analysis of a single-center cohort of patients with CTEPH with an available computed tomography of the abdomen and pelvis (CTAP). PMI was measured at the L3 level of the CTAP and was then calculated using the formula (left psoas area + right psoas area/height2). Patients in the first quartile of PMI were classified as sarcopenic. Results: We reviewed 558 patients with CTEPH, and 97 patients had an available CTAP before intervention. Sarcopenia was identified in 26 (24.8%) of the patients and was associated with worse baseline functional status (p = 0.008), higher mean pulmonary artery pressure (48 vs. 39 mmHg; p = 0.002), and higher pulmonary vascular resistance (9.9 vs. 6.8 WU; p = 0.013). Post-PTE, patients with sarcopenia exhibited longer intensive care unit (ICU) (9 vs. 4 days, p < 0.001) and overall hospital stays (24 vs. 11 days, p < 0.001), despite similar post-operative hemodynamics achieved compared to non-sarcopenic patients. Conclusions: CTEPH patients with sarcopenia have worse baseline functional class and hemodynamics. For those with sarcopenia requiring surgery, there is longer ICU and total hospitalization stays, but they achieve significant functional improvements and hemodynamics comparable to that of non-sarcopenic patients. Hence, the risk of longer perioperative hospitalization days is justified by the longer-term benefit of hemodynamic improvement. The use of PMI as part of routine pre-operative assessments could improve clinical decision-making in CTEPH patients undergoing surgical or medical intervention.